



UNIVERSITY OF PISA

School of Graduate Studies
"Scienza del Farmaco e delle Sostanze Bioattive"

PhD THESIS
2009-2011

**"Synthesis of new enzyme inhibitors as potential
tools for the antineoplastic therapy"**

Giulia Nesi

TUTOR
Dr. Simona Rapposelli

DIRECTOR OF THE SCHOOL
Prof. Claudia Martini

CHIM/08

2012

INDEX

1. PI3K/Akt/PDK1 pathway	7
1.1. PI3K	10
1.1.1 Structure	10
1.1.2. Classification	11
1.1.2.1. Class I _A	12
1.1.2.2. Class I _B	13
1.1.2.3. Class II	14
1.1.2.4. Class III	15
1.1.3. PI3K signal pathway	15
1.1.4. Physiological role of PI3K	16
1.1.4.1. Immunology	16
1.1.4.2. Regulation of glucose transport	16
1.1.5. Alteration of PI3K	18
1.1.5.1. Cancer	18
1.2. PDK1	20
1.2.1 Structure	21
1.2.2. PDK1 regulation	23
1.2.3. Alteration of PDK1	25
1.2.3.1. Cancer	25
1.3. Akt	26
1.3.1. Structure	27
1.3.1.1. PH domain	27
1.3.1.2. Catalytic domain (kinase domain)	28
1.3.1.3. ATP-binding site	29
1.3.2. Akt regulation	30
1.3.3. Physiological role of Akt	32
1.3.3.1. Cell Growth and Cell Proliferation	32
1.3.3.2. Cell Survival	33
1.3.3.3. Metabolism	34
1.3.3.4. Vascular Effects	34
1.3.4. Alteration of Akt	36
1.3.4.1. Cardiovascular disease	36
1.3.4.2. Diabetes	36
1.3.4.3. Neurological disease	37
1.3.4.4. Cancer	38

1.4. PTEN	40
1.4.1. Structure	41
1.4.2. Mechanism of action of PTEN	42
1.4.3. Physiological role of PTEN	43
1.4.3.1. Role in Cell Cycle regulation	43
1.4.3.2. Regulation of Cell Migration	43
1.4.3.3. Apoptosis	44
1.4.4. Alteration of PTEN	45
1.4.4.1. Cancer	45
1.5. mTOR	46
1.5.1. Structure	46
1.5.2. Regulation of mTOR signalling network	47
1.5.3. Physiological role of mTOR	49
1.5.3.1. Role in Cell Cycle regulation	49
1.5.3.2. Lipid metabolism	49
1.5.3.3. Transcription and ribosome biogenesis	49
1.5.4. Alteration of mTOR	50
1.5.4.1. Cancer	50
Reference chapter 1	51
2. PI3K/PTEN/mTOR pathway inhibitors	56
2.1. RTK Inhibitors	56
2.2. PI3K Inhibitors	57
2.2.1 Inhibitors derivatives from natural products	57
2.2.2. PI3K δ inhibitors	60
2.2.3. PI3K γ inhibitors	60
2.3. mTOR Inhibitors	61
2.3.1. Analogs of Rapamycin	62
2.3.2. mTORC1/mTORC2 dual inhibitors (TORCdIs)	64
2.4. mTOR/PI3K dual inhibitors	65
Reference chapter 2	67
3. PDK1 inhibitors	69
3.1. Bisindolylmaleimides	69
3.2. Indolinones	71
3.3. Pyridinonyl-PDK1 inhibitors	74
3.4. Imidazo[4,5-c]quinolines	76
3.5. Quinazolines	77
3.6. Dibenzo[c,f][2,7]naphthyridines	78

3.7. PDK1 activators and modulators	80
3.8. Derivative of the natural compound	81
Reference chapter 3	83
4. Akt inhibitors	85
4.1. ATPase pocket inhibitors	85
4.1.1. Akt inhibitors derivatives from PKA modulator	85
4.1.2. Pyridines analogs as Akt inhibitors	88
4.1.3. Other ATP-pocket binders of Akt	92
4.2. Phosphoinositide binding pocket of the PH domain	94
4.3. Allosteric Akt inhibitors	98
4.4. Akt antisense oligonucleotides	100
4.5. Pseudosubstrate and Substrate-mimetic inhibitors	100
4.6. Inhibitors of Akt with unknown mechanism of actions	101
Reference chapter 4	103
5. New enzyme inhibitors	107
5.1. Disrupting of Akt/PDK1 pathway	108
5.2. State of Art	113
5.3. Aim of the thesis	115
5.3.1. Synthesis	117
5.3.2. Results and discussion of the derivatives	118
5.3.2.1. Cytotoxicity	118
5.3.2.2. Induction of apoptosis	120
5.3.2.3. Effects of treatments on cell cycle	120
5.3.2.4. Inhibition of Akt phosphorylation	121
5.3.3. Substitution of the tetrahydroisoquinoline moiety	123
5.3.3.1. Synthesis	123
5.3.3.2. Results and discussion	124
5.3.4. Substitution of the acetamido linker with a 5-aminosulfonyl chain	125
5.3.4.1. Synthesis	126
5.3.4.2. Results and discussion of 5-aminosulfonyl chain	127
5.3.5. The replacement of the 5-amido moiety with 5-sulfonylamino group	128
5.3.5.1. Synthesis	128
5.3.5.2. Results and discussion of 5-sulfonylamido chain	129
5.3.6. Substitution of the acetamido chain with a electron-rich linker	130
5.3.6.1. Synthesis of urea-derivatives of serie D	131
5.3.6.2. Synthesis of sulfonilureidic-derivatives of serie E	133
5.3.7. Conclusion	134

Reference chapter 5	135
6. Experimental section	137
6.1. Chemistry Methods	137
6.1.1. Elemental Analysis	152
6.2. Biological Methods	154
6.2.1. Drugs and chemicals	154
6.2.2. Cell lines	154
6.2.3. Assay of cytotoxicity	154
6.2.4. Cell-cycle analysis	155
6.2.5. Analysis of apoptosis	155
6.2.6. Akt Phosphorylation	155
6.2.7. Statistical analysis	156
6.2.8. Kinase-specific assay	156